Disposition of 2985 shares by Ori Gutwerg of ANI Pharmaceuticals at 67.0 subject to Rule 16b-3
| BSFA Stock | 51.00 0.00 0.00% |
Slightly above 61% of ANI Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in ANI Pharmaceuticals suggests that many traders are alarmed regarding ANI Pharmaceuticals' prospects. ANI Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, ANI Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
ANI |
Filed transaction by ANI Pharmaceuticals Officer: Svp, Generics. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
ANI Pharmaceuticals Fundamental Analysis
We analyze ANI Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
ANI Pharmaceuticals is rated fourth in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
ANI Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ANI Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
ANI Pharmaceuticals Related Equities
| LP6 | LIVZON PHARMAC | 6.25 | ||||
| EVT | Evotec SE | 0.72 | ||||
| MRK | Merck KGaA | 0.18 | ||||
| H6D | Haleon PLC | 0.00 | ||||
| R2WA | BEXIMCO PHARMAGDR | 0.00 | ||||
| CJH | CanSino Biologics | 0.00 | ||||
| BSFA | ANI Pharmaceuticals | 0.00 | ||||
| S2P | SIMCERE PHARMAC | 0.00 | ||||
| DMP | Dermapharm Holding | 0.26 |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.